



Evaluation of Adipose Derived Stem Cell Therapy in a Canine Model of Multiple Sclerosis

Thesis presented by
Ahmed Nour El-Dine Abdallah
(B. V. Sc., 2011)
(M.V.Sc., 2015)

For fulfilling the degree of PhD.
(Surgery, Anesthesiology and Radiology)

Under the Supervision of

***Prof. Dr. Ashraf Aly Eldesoky
Shamaa***

Professor and Head of Surgery,
Anesthesiology and Radiology Department
Faculty of Veterinary Medicine,
Cairo University

***Prof. Dr. Omar Mohammed Salah
El-Din El-Tookhy***

Professor of Surgery,
Anesthesiology and Radiology
Faculty of Veterinary Medicine,
Cairo University

Prof. Dr. Momtaz Abd-Elhady Shahin

Chief Researcher of Virology
Director of Animal Health Research Institute, Dokki, Giza

2018

Supervision Sheet

Evaluation of Adipose Derived Stem Cell Therapy in a Canine Model of Multiple Sclerosis

Thesis presented by:

Ahmed Nour El-Dine Abdallah

(B. V. Sc., Cairo University, 2011)

(M.V.Sc., Cairo University, 2015)

For fulfilling the degree of PhD.

(Surgery, Anesthesiology and Radiology)

SUPERVISION COMMITTEE:

Prof. Dr. Ashraf Aly Eldesoky Shamaa

Professor and Head of Surgery, Anesthesiology and Radiology Department.
Faculty of Veterinary Medicine, Cairo University.

Prof. Dr. Omar Mohammed Salah El-Din El-Tookhy

Professor of Surgery, Anesthesiology and Radiology. Faculty of Veterinary
Medicine, Cairo University.

Prof. Dr. Momtaz Abd-Elhady Shahin

Chief Researcher of Virology, Director of Animal Health Research Institute,
Dokki, Giza.

Cairo University
Faculty of Veterinary Medicine
Department of Surgery, Anesthesiology & Radiology.

Name : Ahmed Nour El-Dine Abdallah
Birth date : 11/5/1988
Place of Birth : Giza
Nationality : Egyptian
Scientific degree : PhD
Specification : Surgery, Anesthesiology and Radiology
Thesis title : Evaluation of Adipose Derived Stem Cell Therapy in a Canine Model of Multiple Sclerosis

Supervisors:

Prof. Dr. Ashraf Aly El-Desoky Shamaa

Professor and Head of Surgery, Anesthesiology and Radiology Department. Faculty of Veterinary Medicine, Cairo University.

Prof. Dr. Omar Mohammed Salah El-Din El-Tookhy

Professor of Surgery, Anesthesiology and Radiology. Faculty of Veterinary Medicine, Cairo University.

Prof. Dr. Momtaz Abd-Elhady Shahin

Chief Researcher of Virology, Director of Animal Health Research Institute, Dokki, Giza.

Abstract:

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system, whose etiology remains unknown. MS destroys oligodendrocytes, which are the cells responsible for creating and maintaining the myelin sheath, which helps the neurons carry electrical signals. This work aimed to evaluate the treatment of experimentally induced MS in dogs using laser activated adipose derived stem cells. Twenty-four animals were used in study divided into 2 main groups. All animals received bilateral intraspinal injection of 20 μ l of 0.1 % Ethidium bromide in the lateral columns using a microneedle syringe attached to a capillary tube through a drilled hole at the first lumbar vertebra. Treatment using prepared Stem cell preparation was applied by injection of (10×10^6 nucleated cells) directly in the CSF at the day 14 from the induction of the MS. Results showed amelioration of the clinical signs over time confirmed by the resolution of the previous lesions on MRI. Histopathology showed that injecting stem cells directly into the CSF lead to positive migration of the cells and homing into the site of the lesion as confirmed by PKH26 stain. Therapy lead to marked inhibition of apoptotic activity, decreasing inflammation and glial scar formation, regeneration of the destructed axons, remyelination of the lost myelin as detected by increasing of Myelin Basic Proteins and differentiated into oligodendrocyte progenitors expressing Olig2 marker. The electron microscopy showed the remyelination sequence till forming a dense myelin sheath around the axons. From the forementioned results we concluded that treatment using laser activated stem cells holds a promising therapeutic option for treatment of MS.

Keywords: Multiple sclerosis; demyelination; spinal cord; Dog model; Adipose derived stem cells; low level Laser irradiation.

I dedicate this thesis:

*To my family, especially my dear
Mother for her unconditioned endless
love, great support and encouragement
in every step of my life.*

Acknowledgment

First of all, I am greatly indebted to gracious ALLAH who helped me out to carry all the work,

*I wish to express my profound gratitude and high appreciation where all the words of acknowledgement come in short of describing my great indebtedness of thanks to **Prof. Dr. Ashraf Ali Shamaa**, Professor of Surgery, Anesthesiology and Radiology department; Faculty of Veterinary Medicine, Cairo University, for his keen supervision, faithful guidance, advice, unfailing patience and encouragement throughout the progress of work,*

*Sincere thanks are due to **Prof. Dr. Omar Salah EL-Tookhy**, Professor of Surgery, Anesthesiology and Radiology department; Faculty of Veterinary Medicine, Cairo University, for his keen supervision, valuable guidance, help and encouragement during the performance of the work,*

*I owe deep thanks to **Prof. Dr. Momtaz Abd-Elhady Shahin** Professor of Virology, Director of Animal Health Research Institute, Dokki, for her keen and great help in delivering this work, keen supervision and encouragement.*

*I wish to acknowledge **Prof. Dr. Allam Nafady** Professor of Pathology, Pathology department; Faculty of Veterinary Medicine, Assuit University, for his sincere help in electron microscopic analysis and fruitful collaboration.*

Table of Contents

List of figures	Error! Bookmark not defined.
List of abbreviations	Error! Bookmark not defined.
Introduction	Error! Bookmark not defined.
Review of Literature	Error! Bookmark not defined.
A. Multiple Sclerosis	Error! Bookmark not defined.
1. Definition:	Error! Bookmark not defined.
2. Etiology:.....	Error! Bookmark not defined.
2.1. Immunologic factors:	Error! Bookmark not defined.
2.2. Environmental factors:.....	Error! Bookmark not defined.
2.3. Infectious factors:.....	Error! Bookmark not defined.
2.4. Genetic factors:	Error! Bookmark not defined.
3. Types of MS:.....	Error! Bookmark not defined.
4. Pathophysiology of MS:.....	Error! Bookmark not defined.
5. Spinal cord damage:.....	Error! Bookmark not defined.
6. Demyelination patterns:	Error! Bookmark not defined.
7. Diagnosis using special MRI methods:.....	Error! Bookmark not defined.
8. Experimentally Induced Animal Models of MS:	Error! Bookmark not defined.
9. Dogs and demyelinating disorders:.....	Error! Bookmark not defined.
B. Stem cell therapies:	Error! Bookmark not defined.
1. Overview	Error! Bookmark not defined.
2. Cell types used:	Error! Bookmark not defined.
3. Mesenchymal Stem Cells:.....	Error! Bookmark not defined.
3.1. In vitro neuroprotective features of MSC	Error! Bookmark not defined.
3.2. In vivo neuroprotective features of MSC.....	Error! Bookmark not defined.
3.3. In vitro immunomodulatory features of MSC.....	Error! Bookmark not defined.
3.4. In vivo immunomodulatory effects of MSC	Error! Bookmark not defined.
3.5. Homing of grafted MSCs:.....	Error! Bookmark not defined.
3.6. Differentiation of MSCs into neural progenitors:	Error! Bookmark not defined.
3.7. Anti-Apoptic effects of MSCs	Error! Bookmark not defined.
4. Adipose Derived Stem cells:.....	Error! Bookmark not defined.
4.1. ADSCs in MS models:.....	Error! Bookmark not defined.

4.2. Non-Expanded ADSCs:	Error! Bookmark not defined.
C. Low Level Laser Irradiation	Error! Bookmark not defined.
Materials and Methods	Error! Bookmark not defined.
Results	Error! Bookmark not defined.
Discussion	Error! Bookmark not defined.
Conclusion	Error! Bookmark not defined.
References	Error! Bookmark not defined.
Summary	Error! Bookmark not defined.
الملخص	Error! Bookmark not defined.
المستخلص	Error! Bookmark not defined.

List of figures

Figure 1: an illustration of the minimal invasive technique applying only a small hole in the dorsal lamina of the vertebra without exposing the spinal cord.	50
Figure 2: the operation of the hole drilling in the dorsal lamina of the lumbar vertebra.	50
Figure 3: the Hole made in the dorsal lamina of the vertebra (Blue arrow).	51
Figure 4: the special microneedle attached to an inner capillary tube used for injection of the gliotoxin.	51
Figure 5: the process of injection of the gliotoxin into the lateral column of the spinal cord through the hole that was made in the dorsal lamina of the vertebra.	52
Figure 6: the collection of adipose tissue from the abdomen.	54
Figure 7: the adipose tissue ready for processing.	54
Figure 8: the low-level laser device used for activation of the cells.	56
Figure 9: the stem cells were activated using the Adilight device for 20 minutes.	56
Figure 10: the landmarks for demarcation of the approximate location of the proximal cistern.	58
Figure 11: the flow of the CSF after removal of the stylet. This was the positive confirmation that the needle was inserted at the correct place.	58
Figure 12: the process of injection of the cells into the CSF through the foramen magnum.	59
Figure 13: the progressive deficit in clinical manifestation according to the Olby gait score analysis. Data expressed as Mean Values.	65
Figure 14: some of the clinical manifestations appearing on dogs of the second group after induction of the disease.	65
Figure 15: MRI findings of the first group	67
Figure 16: the white matter of the dogs' spinal cord 3 rd day post induction showing mild decrease in staining affinity, no vacuoles were or specific lesions were detected. H&E 200X.	69
Figure 17: diffuse gliosis around axons with signs of intoxication as distorted axons, axonal swelling and partial separation of myelin sheath. H&E 400X.	69
Figure 18: the dog's spinal cord at the 7 th day where very low staining affinity was clear, H&E 200X.	70
Figure 19: the lesions at the 7 th day post induction showing Wallerian degeneration, demyelination and appearance of multinucleated foamy gitter cells (black arrow). H&E 400X.	70
Figure 20: the spinal cord of the dog 14 th day post induction showing multiple vacuolated areas (black arrows) in the white matter. H&E 200X.	71
Figure 21: the spinal cord of the dog 14 th day post induction characterized by multiple circumscribed vacuoles (black arrows) associated with demyelination and axonal degeneration. H&E 400X.	71
Figure 22: the dog's spinal cord 28 th day post induction showing multiple circumscribed vacuolated areas (black arrows) and loss of architecture. H&E 200X.	72
Figure 23: the dog's spinal cord 28 th day post induction showing severe loss of architecture, axonal degeneration and gliosis. H&E 400X	72

Figure 24: immunohistochemical analysis of anti Bax stained sections of the spinal cord representing the lesions at the 3 rd day showing moderate increase in Bax positively stained cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	74
Figure 25: immunohistochemical analysis of anti Bax stained sections of the spinal cord representing the lesions at the 7 th showing marked diffuse increase of Bax reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	74
Figure 26: immunohistochemical analysis of anti Bax stained sections of the spinal cord representing the lesions at the 14 th day showing focal areas of Bax reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	75
Figure 27: immunohistochemical analysis of anti Bax stained sections of the spinal cord representing the lesions at 28 th day showing mild to no Bax reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	75
Figure 28: the immunohistochemical analysis of the Caspase 9 stained section representing the lesions at the 3 rd day showing a marked reactivity at most of the glial cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	76
Figure 29: the immunohistochemical analysis of the Caspase 9 stained section representing the lesions at the 7 th day showing marked reactivity of the glial cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	76
Figure 30: the immunohistochemical analysis of the Caspase 9 stained section representing the lesions at the 14 th day showing persistence of the reactivity at the glial cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	77
Figure 31: the immunohistochemical analysis of the Caspase 9 stained section representing persistence of the reactivity at the glial cells that remained till 28 th day with marked loss of architecture. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	77
Figure 32: the immunohistochemical analysis of Anti MBP representing the lesions the 3 rd day high reaction of around axons. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	78
Figure 33: the immunohistochemical analysis of Anti MBP representing the lesions the 7 th day, showing faintly stained Myelin at the white matter. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	78
Figure 34: the immunohistochemical analysis of Anti MBP representing the lesions the 14 th day showing very mildly stained myelin proteins and restricted to peripheries. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	79
Figure 35: the immunohistochemical analysis of Anti MBP representing the lesions the 28 th day, showing nearly absent reaction of Myelin Basic protein. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	79
Figure 36: immunohistochemical analysis against Olig-2 representing the lesions the 3 rd day showing mild reaction at the periphery of the white matter. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	80
Figure 37: immunohistochemical analysis against Olig-2 representing the lesions the 7 th day showing no reactivity in the white matter. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	80
Figure 38: immunohistochemical analysis against Olig-2 representing the lesions the 14 th day showing no reactivity in the white matter. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	81

Figure 39: immunohistochemical analysis against Olig-2 representing the lesions the 28 th day showing no reactivity in the white matter. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	81
Figure 40: the immunohistochemical analysis against GFAP representing the lesions the 3 rd day showing normal reaction. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	82
Figure 41: the immunohistochemical analysis against GFAP representing the lesions the 7 th day showing mild increase in reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	82
Figure 42: the immunohistochemical analysis against GFAP representing the lesions the 14 th day showing strong increase in reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	83
Figure 43: the immunohistochemical analysis against GFAP representing the lesions the 28 th day showing very high increase in reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	83
Figure 44: the light microscopic analysis of the semi-thin sections of the white matter the 3 rd day showing variation in myelination affinity.	85
Figure 45: the light microscopic analysis of the semi-thin sections of the white matter the 7 th day characterized by separation of the myelin sheath and splitting of its lamellae.	85
Figure 46: the light microscopic analysis of the semi-thin sections of the white matter the 14 th days showing demyelination of the axons and separation of the myelin sheath axonal degeneration.	86
Figure 47: the light microscopic analysis of the semi-thin sections of the white matter the 28 th day showing extensive axonal distortion, demyelination and vacuolation.	86
Figure 48: the EM analysis of the white matter of the first group	88
Figure 49: the progressive amelioration of the clinical signs according to the Olby gait score analysis. Data expressed as Mean values.	90
Figure 50: the MRI analysis of the spinal cord of the treated group animals	91
Figure 51: the fluorescence microscopic analysis of the spinal cord labelled cells with PKH26 stain where a) represents the samples after 3 rd days' post treatment showing few number of positively stained cells and b) represents the samples of the 7 th day showing increase in number of positively stained cells. (Mag. 100X)	92
Figure 52: the spinal cord of the dog 3 rd day post treatment showing marked vacuolated areas (black arrows) with low staining affinity of the white matter. H&E 100X.	93
Figure 53: the spinal cord of the dog 3 rd day post treatment showing circumscribed vacuolated areas (black arrow) with destructed axons and loss of architecture. H&E 400X.	93
Figure 54: the spinal cord of the dog 7 th day post treatment showing small patchy areas of remyelination. H&E 100X.	94
Figure 55: the spinal cord of the dog 7 th day post treatment showing the appearance of large cells with deeply stained nucleus (black arrows) and active remyelinating activity. H&E 200X.	94
Figure 56: the spinal cord of the dog 14 th day post treatment showing large areas of patchy remyelination. H&E 100X	95
Figure 57: the spinal cord of the dog at the 14 th day post treatment showing increase in number of the large deeply nucleated cells and active remyelination areas. H&E 200X.	95

Figure 58: the spinal cord of the dog at the 28 th day post treatment with homogenous deeply stained white matter. H&E 100X.	96
Figure 59: the spinal cord of the dog at the 28 th day post treatment showing remyelination of most of the axons. H&E 400X.	96
Figure 60: the dog spinal cord analysis to Bax 3 rd day post treatment showing mild reactivity. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	97
Figure 61: the dog spinal cord 7 th day post treatment showing increased reactivity to the Bax antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	98
Figure 62: the dog spinal cord the 14 th day post treatment showing mild reactivity to Bax antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	98
Figure 63: the dog spinal cord the 28 th day showing very low reactivity to Bax antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	99
Figure 64: the dog spinal cord the 3 rd day post treatment with moderate reaction to caspase-9 antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	99
Figure 65: the dog spinal cord at the 7 th day post treatment with mild reaction against caspase-9 antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	100
Figure 66: the dog spinal cord at the 14 th day post treatment with no reaction against caspase-9 antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	100
Figure 67: the dog spinal cord at the 28 th day post treatment with no reaction against caspase-9 antibodies. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	101
Figure 68: the dog spinal cord the 3 rd day post treatment with low reactivity of the MBP and moderate reaction at the periphery of the white matter (right side). Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	101
Figure 69: the dog spinal cord at the 7 th day post treatment with an increase and homogenous reaction to MBP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	102
Figure 70: the dog spinal cord at the 14 th day post treatment characterized by deeply stained MBP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	102
Figure 71: the dog spinal cord at the 28 th day post treatment characterized by marked increase in MBP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	103
Figure 72: the dog spinal cord at the 3 rd day post treatment showing the appearance of olig 2 positive cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	103
Figure 73: the dog spinal cord at the 7 th day post treatment showing an increase in olig 2 positive cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	104

Figure 74: the dog spinal cord at the 14 th day post treatment showing a decrease in olig 2 positive cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	104
Figure 75: the dog spinal cord at the 28 th day post treatment showing low number of olig 2 positive cells. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	105
Figure 76: the dog spinal cord of the dog at the 3 rd day post treatment showing low reaction against GFAP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	105
Figure 77: the dog spinal cord at the 7 th day post treatment showing moderate reactivity against GFAP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	106
Figure 78: the dog spinal cord at 14 th day post treatment showing moderate reactivity against GFAP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	106
Figure 79: the dog spinal cord at the 28 th day post treatment showing moderate reactivity against GFAP. Avidinbiotin immune-peroxidase complex counter stain hematoxylin 400X.	107
Figure 80: light microscopic analysis of the semithin sections stained by toluidine blue at the 3 rd day post treatment showing extensive demyelination, separation of myelin sheath and multiple vacuolation.	108
Figure 81: light microscopic analysis of the semithin sections stained by toluidine blue at the 7 th day post treatment showing the beginning of the remyelinating activity while other axons are still having deformities and separated myelin sheath and or demyelination.	109
Figure 82: light microscopic analysis of the semithin sections stained by toluidine blue at the 14 th day post treatment showing high remyelinating activity where most of the axons were covered by myelin sheaths with different staining affinity.	109
Figure 83: light microscopic analysis of the semithin sections stained by toluidine blue at the 28 th day post treatment showing the high staining affinity of the newly formed myelin sheaths.	110
Figure 84: T.E.M. analysis of the spinal cord of the second group.	111
Figure 85: the scores of the remyelination of the white matter, Data expressed as Mean. HP=Histopathology, MBP=Myelin Basic Proteins, TB= Toluidine Blue, DPT=Days post treatment.	112

List of abbreviations

ADEM	acute disseminated encephalomyelitis
ADSCs	Adipose Derived Stem Cells
BBB	blood-brain barrier
BDNF	Brain derived neurotrophic factor
BMSCs	Bone marrow-derived stromal cells
CDV	Canine Distemper Virus
CNS	Central Nervous System
CNTF	Ciliary neurotrophic factor
CSF	cerebrospinal fluid
EAE	Experimental autoimmune/allergic encephalomyelitis
EGF	Epidermal growth factor
EM	Electron microscopy
ESCs	Embryonic Stem Cells
FGF	basic fibroblast growth factor
GFAP	Glial Fibrillary Acidic Proteins
HGF	Hepatocyte growth factor
HSCs	Hematopoietic Stem Cells
iPSCs	Pluripotent Stem Cells
LPC	lysophosphatidylcholine
MBP	Myelin Basic Protein
MI	Myocardial Infarction
MRI	Magnetic Resonance Imaging
MS	Multiple sclerosis
MSCs	Mesenchymal Stem Cells
NGF	Nerve growth factor
NSCs	Neural Stem Cells
OPCs	Oligodendrocyte Progenitor Cells
PNS	peripheral nervous system
PPMS	Primary Progressive Multiple sclerosis
PRMS	Progressive Relapsing Multiple sclerosis
RRMS	Relapsing-Remitting Multiple sclerosis
SCI	Spinal Cord Injury
SPMS	Secondary Progressive Multiple sclerosis
SVF	stromal vascular fraction
TGF- β	Transforming growth factor beta
TMEV	Theiler's murine encephalomyelitis virus
VEGF	vascular-endothelial growth factor

Introduction

Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system (CNS) which can lead to severe physical and cognitive disability and neurological defects. Damage of this myelin sheath protecting the nerve cells in the brain and spinal cord progresses to damage or destruction of the axons (nerve fibers) over time leading to irreversible neurodegeneration explaining the progression of the disease and the increase in disability (**Compans and Cooper, 2008**).

Although the etiology of MS is yet obscure, some researches demonstrated that the cause of MS is multifactorial and includes the genetic predisposition, infectious agents and environmental influences (**Barnett and Sutton, 2006**). Over the past several decades, a number of animal models have been developed in order to understand different aspects of MS (**Denic et al., 2011**). Many breeds of Dogs are hereditarily subjected to demyelination of the CNS and the Canine Distemper encephalitis was initially described as “acute MS of the dog” by human neuropathologists making them an ideal model for studying MS yet very little studies were conducted on dogs (**Pachner, 2011**).

Unfortunately, there is no definite cure for MS and current remedies only help in alleviating the symptoms and halting the immune attack (**Uccelli et al., 2013**). But Stem cell therapies can offer a new hope for the treatment of such neurological diseases, by differentiating into oligodendrocytes and astrocytes (**Pittenger et al., 1999**) and secreting neurotrophic factors with immunomodulatory effects that could prevent further cellular damage and providing a regenerative microenvironment for remyelination (**Caplan and Dennis, 2006 and Cohen, 2013**) Adipose Derived Stem Cells (ADSCs) can be harvested by minimally invasive procedures that should facilitate their use in cell transplantation (**Tsuji et al., 2014**). These cells are capable to differentiate to other cells outside their lineage, such as neural progenitors and oligodendrocytes. Many of the neurotrophic factors have been identified as secretome of ADSCs (**Ghasemi et al., 2014**).